Novedades en stents farmacoactivos. Actualización y futuros desarrollos

Finn, 2010, Future directions in stenting, Expert Rev Cardiovasc Ther, 8, 1, 10.1586/erc.09.144 Nakazawa, 2009, A review of current devices and a look at new technology: drug-eluting stents, Expert Rev Med Devices, 6, 33, 10.1586/17434440.6.1.33 Ramcharitar, 2008, Fully biodegradable coronary stents. Progress to date, Am J Cardiovasc Drugs, 8, 305, 10.2165/00129784-200808050-00003 Duckers, 2007, EuroIntervention, 3, 350, 10.4244/EIJV3I3A64 Serra, 2007, Análisis y características de los stents farmacoactivos disponibles en la actualidad. Futuros desarrollos, Rev Esp Cardiol Supl, 7, E8 O’Brien, 2009, The evolution of cardiovascular stent materials and surfaces in response to clinical drivers: A review, Acta Materialia, 5, 945 Schmidt, 2009, A comparison of the mechanical performance characteristics of seven drug-eluting stent systems, Catheter Cardiovasc Interv, 73, 350, 10.1002/ccd.21832 Stone, 2009, for the SPIRIT IV Investigators. TCT 2009 abstract: a large-scale randomized comparison of everolimus-eluting stents and paclitaxel-eluting stents: one-year clinical outcomes from the SPIRIT IV trial, Am J Cardiol, 140, XV Kedhi, 2010, Second-generation everolimus-eluting and paclitaxel-eluting stents in real-life practice (COMPARE): a randomised trial, Lancet, 375, 201, 10.1016/S0140-6736(09)62127-9 Meredith, 2009, for the RESOLUTE Investigators. Clinical and angiographic results with the next-generation resolute stent system: a prospective, multicenter, first-inhuman trial, JACC Cardiovasc Interv, 2, 977, 10.1016/j.jcin.2009.07.007 Meredith, 2010, for the RESOLUTE Investigators. Longterm clinical outcomes with the next-generation Resolute Stent System: a report of the two-year follow-up from the RESOLUTE clinical trial, EuroIntervention, 5, 692, 10.4244/EIJV5I6A114 Windecker, 2008, Biolimus-eluting stent with biodegradable polymer versus sirolimus-eluting stent with durable polymer for coronary revascularisation (LEADERS): a randomised non-inferiority trial, Lancet, 372, 1163, 10.1016/S0140-6736(08)61244-1 Chevalier, 2009, NOBORI 1 Clinical Investigators. Randomized comparison of the Nobori Biolimus A9-eluting coronary stent with the Taxus Liberté paclitaxel-eluting coronary stent in patients with stenosis in native coronary arteries: the NOBORI 1 trial —Phase 2, Circ Cardiovasc Interv, 2, 188, 10.1161/CIRCINTERVENTIONS.108.823443 Ruef, 2010, Increased restenosis rates 12 months after coronary implantation of the sirolimuseluting YUKON —choice stent compared to the paclitaxeleluting TAXUS stent, Clin Cardiol, 33, E33 Cervinka P, Bystron M, Spacek R, Kvasnak M, Jakabcin J. Randomized comparison of Genous stent versus Chromium-Cobalt stent for treatment of ST elevation myocardial infarction. 6 months clinical angiographic and IVUS followup. GENIUS-STEMI trial. Presentado en: ACC I2 Summit 2009. Orlando, 28 de marzo de 2009. Karjalainen, 2009, Long-term clinical outcome with titanium-nitrideoxide- coated stents and paclitaxel-eluting stents for coronary revascularization in an unselected population, Int J Cardiol